Spotlight On... Medtronic divulges Type 2 diabetes outcomes data for MiniMed; Medtronic's Ishrak tops on S&P CEO 2015 raise list; FDA sets May panel for St. Jude PFO occluder; and more...

Medtronic ($MDT) has released the latest study results from its MiniMed insulin pumps. The 12-month data show that after crossing over to MiniMed from 6 months of multiple daily insulin (MDI) injections, A1C reduction improved from 0.4% to 0.8% while using 19% less insulin. The company said this is the largest randomized, controlled trial to compare efficacy and safety of insulin pumps versus multiple daily insulin injections in patients with poorly controlled Type 2 diabetes. "We found that participants who switched from MDI to insulin pumps were able to achieve these same results by the 12-month mark," said Dr. Ronnie Aronson, the lead author of the continuation study phase and executive director at LMC Diabetes & Endocrinology in Canada, in a statement. "Given that many patients with type 2 diabetes have difficulty achieving glycemic control, these additional data demonstrate that insulin pumps provide a significant advantage over MDI with a safe and consistent effect." More

@FierceMedDev: ICYMI yesterday: Belgian startup raises €10M to back CE mark trial for micro-invasive glaucoma implant. Report | Follow @FierceMedDev

@EmilyWFierce: Merck KGaA loses FDA approval for fertility drug after abandoning postmarketing studies. FiercePharmaMarketing story | Follow @EmilyWFierce

> Medtronic chairman and CEO Omar Ishrak reportedly got the second-largest raise of any CEO in the S&P 500 in 2015--$32 million. Article

> The FDA has set a May 24 panel date to review St. Jude Medical's ($STJ) Amplatzer Patent Foramen Ovale (PFO) Occluder, which is a percutaneously delivered permanent cardiac implant for PFO closure. It's indicated to prevent recurrent ischemic stroke in patients who have had a cryptogenic stroke due to a presumed paradoxical embolism. FDA notice

> University of California, Irvine, researchers will conduct a study of cerebral microbleeds (CMB) in high school football players as a precursor to chronic traumatic encephalopathy. The trial will use a Toshiba MRI system. More

Biotech News

@FierceBiotech: Forbion raises $200M for EU and North American biotechs. Article | Follow @FierceBiotech

@JohnCFierce: Serious question: Does celebrity science mean much in drug development? | Follow @JohnCFierce

> U.S. docs know scarily little about the FDA process for new drugs. Article

> Merck, ALK's dust mite immunotherapy gains FDA review. Story

> Langer-backed startup Kala Pharma bags $68M round for PhIII drive. Report

Pharma News

@FiercePharma: Pharma primed to invest in patient-centric services, but will patients get the message? More from FiercePharmaMarketing | Follow @FiercePharma

> Horizon reworks financial forecast; investors not happy. Story

> AstraZeneca's $3B push for Tagrisso gets a leg up from Clovis setback. Report

> Sanofi could go hostile with Medivation bid after initial rejection: Bloomberg. Article

Biotech Research News

> London University spinoff hails new tooth repair technology. Article

> UCSD targets dendritic spines in promising Alzheimer's approach. More

> Altered states: Imperial investigators explore the promise of LSD for depression. Story

> C-Myc oncogene determines function of immune cells. Report

> Baylor scientists ID dendritic cells as new cancer therapy targets. Article

Vaccines News

> Worldwide switch to bivalent oral polio vaccine to kick off on Sunday. News

> ASCO pushes more HPV vaccine use in published recommendations. More

> Pfizer to 'spotlight' vaccines following Allergan bust, firm predicts. Story

> Immunovaccine pairs with security firm Leidos on Zika work. Report

> Kaketsuken in talks with Astellas to sell its vaccines business. Article

Pharma Marketing News

> AstraZeneca's Tagrisso eyes market advantage as Clovis rival hits a wall. Item

> In Shkreli's aftermath, KaloBios vows fair pricing. Will others follow its lead? More

> Pharma primed to invest in patient-centric services, but will patients get the message? Report

> AbbVie, Roche look for blockbuster boost from $110K leukemia med Venclexta. Story

> Merck KGaA loses FDA approval for fertility drug after abandoning postmarketing studies. Article